Jordan brings over 10 years of experience as a peptide chemist, over which time he has authored several high impact publications, including in Science and JACS. Prior to joining Rosa, Jordan helped develop the science behind the company's technology. He is heading up our research and development operations at Rosa.
Andy has transformed multiple early-stage technologies into new science spin-outs; raised more than £2M of angel, VC and grant funding; built extensive contacts in target markets; and contributed to national innovation strategy for synthetic biology. He completed his PhD in cancer research from the Cancer Research UK Centre at the University of Birmingham.
Bristol is one of the leading research institutions in the UK. It was ranked within the top 5% in the QS World University rankings 2019. The School of Chemistry is internationally recognised for the quality of its research, and was ranked within the top 4 Chemistry departments in the UK in the research excellence framework (REF) 2014.
A world leader in protein design
with a track record of commercial partnerships, Dek's research underpins Rosa's technology. His work has been featured in Nature Chemistry (cover story), Nature Chemical Biology and Science. He is the recipient of multiple science awards from bodies including the Royal Society and the Royal Society of Chemistry.
Chris brings over 30 years’ experience in the pharmaceutical industry. He is currently a director at the Centre for Therapeutic Innovation at the University of Bath. From 2009-16, Chris led Global Pharmaceutical Development at AstraZeneca and was responsible for developing new medicines from discovery, through development, to post launch optimisation.
Jon brings over 30 years of experience in the software and hardware industry. In 1996, Jon founded Cramer and was CEO of the business for 6 years. Cramer sold to Amdocs in 2006 for $425M. Jon has been an early stage investor in a number of start ups, such as Creo Medical (surgical technology), SwiftKey (AI) and Zynstra (cloud computing).
Laurence is the former Managing Director and co-owner of Tocris Bioscience. During his time with the business, Laurence set up and ran Tocris’ wholly owned US subsidiary. He has invested in and advised a number of start-up and early stage businesses and is currently a Non Executive Director on the boards of Ubiquigent Limited and DeepMatter PLC.
Chris is the founder of Creo Medical, with 20 years of experience in medical device development, including four years at Gyrus Group PLC in his role as Senior Engineer. Chris is a named inventor and lead author on over 300 patents, patent applications and journal publications and was made one of Maserati top 100 Innovators.
Keith is founder and Chairman of the Unit DX incubator. He was Chairman and major backer of Ziylo Ltd, the glucose sensing company sold to Novo Nordisk in 2018. Currently he is an investor/mentor/director for a dozen other early-stage companies and actively supports our efforts on the journey to commercialisation.
Harry completed his PhD in Supramolecular Chemistry at the University of Bristol. His first company – the glucose sensing company Ziylo – was sold to Novo Nordisk for a deal that could exceed $800M. As part of Ziylo's growth, he founded the Unit DX incubator to provide much-needed lab space to science-led companies in Bristol.